- Alovudine
- ALVAC 1433
- AMD070
- AV-1101
- AVX754
- Azodicarbonamide (ADA)
- BMS-488043
- Brecanavir
- Buspirone hydrochloride (Buspar)
- Calanolide A
- Calcium spirulan
- CD4-based therapies
- Cell Genesys gene therapy
- Cimetidine (Dyspamet / Tagamet)
- Colony stimulating factors
- Curcumin
- Dapivirine
- Dextran sulphate
- Dinitrochlorobenzene (DNCB)
- Elvucitabine
- Etravirine
- Extracorporeal photopheresis
- FP-21399
- GPG-NH2
- GS 9137
- GW695634
- GW8248
- HEPT derivatives
- HGP-30
- HGTV43
- Hydroxycarbamide (Hydrea)
- Hyperthermia
- Interferon gamma-1b (Immukin)
- Interleukin-12
- Interleukin-16
- Intravenous immunoglobulin
- Iscador
- Isoprinosine
- JE-2147
- Lentinan
- Malariotherapy
- Maraviroc
- MIV 150
- MK-0518
- MVA-BN-Nef vaccine
- Mycophenolate mofetil (CellCept)
- Ozone
- P-1946
- p24.VLP
- PA-457
- Passive immunotherapy
- Phosphazid
- PN355
- PRO 2000
- PRO 542
- pTHr.HIVA
- Racivir
- Remune
- S-1360
- SJ-3366
- SP1093V
- SPV-30
- Stampidine
- T-1249
- Tat toxoid vaccine
- Thymic peptides
- TMC278
- TNFR:Fc
- TNX-355
- Todoxin
- TSAO derivatives
- Tucaresol
- Vesnarinone
- Vicriviroc
- VIR201
- Virodene P058
- WF10
HGTV43
HGTV43 is an anti-sense treatment designed to produce T cells that are genetically resistant to HIV infection. HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc.
How gene transfer vectors work
Vectors are used to insert new genetic information into target cells. Enzo Biochem's Stealth Vector technique has achieved insertion of new genetic material into 30% of target cells, in laboratory studies. These cells, genetically engineered to provide new biological functions, can then be transferred to people with diseases such as with HIV.
The company claim that the Stealth Vector will not trigger an immune reaction in humans. See Gene therapy in Anti-HIV therapy: Ways of attacking HIV for further information on these approaches.
How HGTV43 works
HGTV43 works by 'turning off' the genes which HIV needs to grow and reproduce in human cells. Engineered genes are inserted directly into cells to regulate the function of the genes essential for HIV replication. These genetically modified CD4 cells are then transferred back to the individual. The theory is that these individuals will thus have a pool of fully functioning CD4 cells immune to HIV infection.
latest aidsmap news
- HIV prevalence may decline because the most vulnerable are infected and die first
- Lack of perceived need for HIV treatment associated with poor adherence
- TB doesn't always increase HIV viral load
- New 75mg darunavir tablet approved by FDA for use by HIV-positive children
- Thyroid checks recommended for people with HIV
- Knighthood for head of UK HIV charity
- Gay men often not accessing PEP despite risk of HIV exposure
- Inflammatory cytokines may contribute to endothelial dysfunction in people with untreated HIV
- Internalised homophobia leads to sexual risk taking by HIV-positive gay men
- Most gay men willing to consider PrEP for possible HIV exposure
